McNeil Recalls Cut J&J's Profits, Draw U.S. Attorney's Subpoena
This article was originally published in The Tan Sheet
Investment analysts are confident in Johnson & Johnson's long-term viability even though recalls of OTC drugs and the temporary closure of the facility where the products were made prompted the firm to slash full-year profits estimates and triggered a federal investigation
You may also be interested in...
As the new head of Johnson & Johnson's beleaguered U.S. OTC business, Pat Mutchler takes on the burden of restoring the firm's reputation and manufacturing quality.
Johnson & Johnson's consumer business missed revised analyst estimates and dragged down overall sales in the third quarter of what can only be called a lost year for the unit
Johnson & Johnson has finished culling its ranks of employees responsible for quality control lapses that led to extensive OTC recalls, according to CEO William Weldon.